Article Text
Concise report
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists
Abstract
Background: Blockage of tumour necrosis factor α (TNFα) is highly effective in rheumatic diseases, especially in rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Furthermore, TNFα antagonists have also been shown to significantly reduce psoriatic skin lesions.
Case reports: A series of nine patients with RA who were treated with different types of TNFα antagonists and who unexpectedly developed either a new onset or an exacerbation of psoriatic skin lesions are reported
- LEF, leflunomide
- MTX, methotrexate
- RA, rheumatoid arthritis
- TNFα, tumour necrosis factor α
- psoriasis
- tumour necrosis factor antagonists
- side effects
- rheumatoid arthritis
Statistics from Altmetric.com
Footnotes
-
↵* S Kary and M Worm contributed equally to this article.
-
Published Online First 8 September 2005